Main Article Content
A comparative trial with combinations of rifampicin, ethambutol and isoniazid (hydronsan) in previously untreated cases of pulmonary tuberculosis
Abstract
The results of a randomized, single-blind, between-patient trial of various combinations of rifampicin, ethambutol, and an INH salt in 100 previously untreated cases of pulmonary tuberculosis are presented. As in earlier trials by the South African State Health Department, 100% of cases on a combination of rifampicin plus INH or INH salt achieved bacteriological conversion within 12 weeks with a mean conversion time of approximately 5 weeks. It is suggested that properly used, rifampicin should be considered for first-line therapy of pulmonary tuberculosis.